SLXN
Silexion Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$0.35
+0.06%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -14.8%
- EBIT
- +176.2%
- EPS
- -20.0%
- Free cash flow
- -17.7%
- Operating cash flow
- -17.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +71.3%
Three-year CAGR
- Revenue
- —
- EBITDA
- +27.9%
- EBIT
- +192.5%
- Net income
- +27.6%
- EPS
- +97.7%
- Free cash flow
- -28.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026